HRP20190178T1 - Farmaceutski sastav za liječenje disglikemije i izleta glukoze - Google Patents

Farmaceutski sastav za liječenje disglikemije i izleta glukoze

Info

Publication number
HRP20190178T1
HRP20190178T1 HRP20190178TT HRP20190178T HRP20190178T1 HR P20190178 T1 HRP20190178 T1 HR P20190178T1 HR P20190178T T HRP20190178T T HR P20190178TT HR P20190178 T HRP20190178 T HR P20190178T HR P20190178 T1 HRP20190178 T1 HR P20190178T1
Authority
HR
Croatia
Prior art keywords
dysglycemia
treating
pharmaceutical composition
glucose excursions
excursions
Prior art date
Application number
HRP20190178TT
Other languages
English (en)
Inventor
Alexander Macgregor
Original Assignee
Alexander Macgregor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexander Macgregor filed Critical Alexander Macgregor
Publication of HRP20190178T1 publication Critical patent/HRP20190178T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HRP20190178TT 2008-08-29 2019-01-28 Farmaceutski sastav za liječenje disglikemije i izleta glukoze HRP20190178T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA002638240A CA2638240C (en) 2008-08-29 2008-08-29 Method of treating dysglycemia and glucose excursions
PCT/CA2009/001166 WO2010022497A1 (en) 2008-08-29 2009-08-24 Method of treating dysglycemia and glucose excursions
EP09809138.2A EP2231128B1 (en) 2008-08-29 2009-08-24 Pharmaceutical composition for treating dysglycemia and glucose excursions

Publications (1)

Publication Number Publication Date
HRP20190178T1 true HRP20190178T1 (hr) 2019-05-03

Family

ID=40030453

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20190178TT HRP20190178T1 (hr) 2008-08-29 2019-01-28 Farmaceutski sastav za liječenje disglikemije i izleta glukoze

Country Status (12)

Country Link
US (1) US9061061B2 (hr)
EP (1) EP2231128B1 (hr)
JP (2) JP2012500810A (hr)
CN (1) CN101909604B (hr)
AU (2) AU2009287368A1 (hr)
BR (1) BRPI0917922A2 (hr)
CA (1) CA2638240C (hr)
ES (1) ES2708498T3 (hr)
HR (1) HRP20190178T1 (hr)
MX (1) MX337175B (hr)
TR (1) TR201901238T4 (hr)
WO (1) WO2010022497A1 (hr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2638240C (en) 2008-08-29 2010-02-02 Alexander Macgregor Method of treating dysglycemia and glucose excursions
DK3370776T3 (da) * 2015-11-06 2024-06-17 Gelteq Ltd Fremgangsmåde og produkt til test af respons på oral glucosedosis
CN110208705A (zh) * 2019-05-09 2019-09-06 赛尔网络有限公司 一种锂电池剩余寿命预测方法及装置
WO2023225307A1 (en) * 2022-05-19 2023-11-23 Insulet Corporation Switching and customization of glucose prediction models in medicament delivery devices

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61280423A (ja) * 1985-06-05 1986-12-11 Kiyuukiyuu Yakuhin Kogyo Kk 口腔内粘膜貼付剤
US4849227A (en) 1986-03-21 1989-07-18 Eurasiam Laboratories, Inc. Pharmaceutical compositions
DE3887681T2 (de) 1987-11-27 1994-05-11 Battelle Memorial Institute, Richland, Wash. Überkritische mizellentrennung in der flüssig-umkehrphase.
US5324280A (en) 1990-04-02 1994-06-28 Alza Corporation Osmotic dosage system for delivering a formulation comprising liquid carrier and drug
WO1994008599A1 (en) 1992-10-14 1994-04-28 The Regents Of The University Of Colorado Ion-pairing of drugs for improved efficacy and delivery
US5858398A (en) 1994-11-03 1999-01-12 Isomed Inc. Microparticular pharmaceutical compositions
US5945125A (en) 1995-02-28 1999-08-31 Temple University Controlled release tablet
US6652837B1 (en) 1996-05-24 2003-11-25 Massachusetts Institute Of Technology Preparation of novel particles for inhalation
FR2775188B1 (fr) 1998-02-23 2001-03-09 Lipha Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption
AP1224A (en) 1998-03-19 2003-11-14 Bristol Myers Squibb Co Biphasic controlled release delivery system for high solubility pharmaceuticals and method.
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US6673612B2 (en) 1999-07-16 2004-01-06 Mirus Corporation Micellar systems
US6086920A (en) 1998-08-12 2000-07-11 Fuisz Technologies Ltd. Disintegratable microspheres
US6099862A (en) 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
PT1183014E (pt) 1999-06-14 2003-12-31 Cosmo Spa Composicoes farmaceuticas orais de libertacao controlada e de dissimulacao de sabor
US20030235595A1 (en) 1999-06-30 2003-12-25 Feng-Jing Chen Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
JP2003520759A (ja) * 1999-08-31 2003-07-08 アンドルックス ファーマスーティカルズ インコーポレーテッド 単位核を有する徐放性錠剤
PL356300A1 (en) * 1999-12-28 2004-06-28 Ajinomoto Co, Inc. Oral preparations for diabetes
US6790459B1 (en) * 2000-11-03 2004-09-14 Andrx Labs, Llc Methods for treating diabetes via administration of controlled release metformin
US20060034922A1 (en) * 2000-11-03 2006-02-16 Andrx Labs, Llc Controlled release metformin compositions
US6960357B2 (en) 2001-05-25 2005-11-01 Mistral Pharma Inc. Chemical delivery device
ITMI20011337A1 (it) 2001-06-26 2002-12-26 Farmatron Ltd Composizioni farmaceutiche orali a rilascio modificato del principio attivo
US20030021841A1 (en) 2001-07-02 2003-01-30 Matharu Amol Singh Pharmaceutical composition
ITFI20010230A1 (it) 2001-11-29 2003-05-29 Menarini Int Operations Lu Sa Composizioni farmaceutiche per il trattamento del diabete mellito di tipo ii
EP1460992B1 (en) * 2001-12-03 2009-03-11 Dor Biopharma, Inc. Stabilized reverse micelle compositions and uses thereof
US20030113366A1 (en) 2001-12-14 2003-06-19 Macgregor Alexander Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents
US7183321B2 (en) * 2001-12-17 2007-02-27 Bristol-Myers Squibb Company Antidiabetic formulation and method
CA2470636A1 (en) 2001-12-20 2003-07-03 Pharmacia Corporation Zero-order sustained released dosage forms and method of making the same
WO2003068209A1 (en) 2002-02-14 2003-08-21 Sonus Pharmaceuticals, Inc. Metformin salts of lipophilic acids
US8323692B2 (en) 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
MXPA04008100A (es) 2002-02-21 2005-06-17 Biovail Lab Int Srl Formulaciones de liberacion modificada de al menos una forma de tramadol.
US20030219482A1 (en) 2002-03-21 2003-11-27 Chaudhari Sunil Sudhakar Multiparticulate compositions for once-a-day administration
WO2003090723A1 (en) 2002-04-23 2003-11-06 Bristol-Myers Squibb Company Modified-release vasopeptidase inhibitor formulation, combinations and method
CN1735418A (zh) 2002-06-07 2006-02-15 拉特格斯州立大学 微胶粒聚集体
US20050051922A1 (en) 2002-09-20 2005-03-10 Avinash Nangia Pharmaceutical composition with sodium lauryl sulfate as an extra-granular absorption/compression enhancer and the process to make the same
WO2004045622A1 (en) 2002-11-15 2004-06-03 Ranbaxy Laboratories Limited Pharmaceutical dosage forms of biguanide-sulfonylurea combinations
FR2851734B1 (fr) 2003-02-28 2006-06-09 Galenix Innovations Procede pour la fabrication d'une composition pharmaceutique sous la forme de comprimes contenant un fibrate et comprimes obtenus selon le procede
US20070219250A1 (en) 2003-11-28 2007-09-20 Romi Singh Pharmaceutical Compositions of Nateglinide
WO2006026556A2 (en) * 2004-08-27 2006-03-09 Spherics, Inc. Bioadhesive rate-controlled oral dosage formulations
EP1559419A1 (en) * 2004-01-23 2005-08-03 Fournier Laboratories Ireland Limited Pharmaceutical formulations comprising metformin and a fibrate, and processes for their obtention
WO2006026504A2 (en) * 2004-08-27 2006-03-09 Spherics, Inc. Mucoadhesive oral formulations of high permeability, high solubility drugs
WO2006082523A2 (en) 2005-01-25 2006-08-10 Aurobindo Pharma Limited Pharmaceutical sustained release composition of metformin
UY29445A1 (es) 2005-03-30 2006-10-02 Generex Pharm Inc Composiciones para la transmisión transmucosa oral de la metformina
CA2604599A1 (en) 2005-04-05 2006-10-12 Universite De Montreal Hydrophilic core polymeric micelles for the delivery of water-soluble compounds
CN103271083B (zh) 2005-10-07 2017-08-11 阿拉巴马大学 多功能离子液体组合物
JP5165582B2 (ja) 2005-12-16 2013-03-21 メルク・シャープ・エンド・ドーム・コーポレイション ジペプチジルペプチダーゼ−４インヒビターとメトホルミンとを組み合わせた医薬組成物
RU2435569C2 (ru) 2006-03-16 2011-12-10 Трис Фарма, Инк. Композиции с модифицированным высвобождением, содержащие комплексы лекарственное вещество - ионообменная смола
DE102006027790A1 (de) 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Typ-2-Diabetes Kombinations-Wafer
US20100003332A1 (en) 2006-07-27 2010-01-07 Amorepacific Corporation Process For Preparing Powder Comprising Nanoparticles of Sparingly Soluble Drug
JP2010502591A (ja) 2006-09-04 2010-01-28 パナセア バイオテック リミテッド プログラム可能な浮揚性送達技術
US20070172525A1 (en) * 2007-03-15 2007-07-26 Ramesh Sesha Anti-diabetic combinations
EP2167048B1 (en) 2007-05-30 2016-10-26 Wockhardt Limited A novel tablet dosage form
EP2231191A2 (en) 2007-12-11 2010-09-29 ConjuChem Biotechnologies Inc. Formulation of insulinotropic peptide conjugates
WO2009080025A1 (en) 2007-12-20 2009-07-02 Fertin Pharma A/S Compressed chewing gum comprising metformin
CN104922683A (zh) 2008-03-21 2015-09-23 米兰制药有限公司 含有蜡的缓释制剂
CA2638240C (en) 2008-08-29 2010-02-02 Alexander Macgregor Method of treating dysglycemia and glucose excursions

Also Published As

Publication number Publication date
WO2010022497A1 (en) 2010-03-04
MX2011002227A (es) 2011-07-29
EP2231128A1 (en) 2010-09-29
BRPI0917922A2 (pt) 2016-07-26
CN101909604B (zh) 2013-08-14
JP2012500810A (ja) 2012-01-12
AU2016228159B2 (en) 2018-04-12
CA2638240C (en) 2010-02-02
US9061061B2 (en) 2015-06-23
AU2009287368A2 (en) 2010-06-24
MX337175B (es) 2016-02-15
TR201901238T4 (tr) 2019-02-21
AU2016228159A1 (en) 2016-10-06
ES2708498T3 (es) 2019-04-09
EP2231128B1 (en) 2018-12-26
CA2638240A1 (en) 2008-11-18
AU2009287368A1 (en) 2010-03-04
EP2231128A4 (en) 2013-11-27
CN101909604A (zh) 2010-12-08
US20110159045A1 (en) 2011-06-30
JP2014159470A (ja) 2014-09-04
JP5902228B2 (ja) 2016-04-13

Similar Documents

Publication Publication Date Title
PL3181134T3 (pl) Bifidobakterie do leczenia cukrzycy i stanów pokrewnych
EP2265605A4 (en) METHOD OF MANUFACTURING DEXLANSOPRAZOLE AND POLYMORPHIDE THEREOF
EP2259796A4 (en) MATERIALS AND METHODS FOR IMPROVED IMMUNE LYCOPROTEINS
ZA201202560B (en) Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes
EP2173732A4 (en) PROCESSES FOR THE PREPARATION OF DOCETAXEL AND POLYMORPHIC
GB0810850D0 (en) Tobacco treatment
HRP20190178T1 (hr) Farmaceutski sastav za liječenje disglikemije i izleta glukoze
EP2321302A4 (en) PROCESS FOR THE PREPARATION OF AZACITIDINE AND POLYMORPHIC
ZA201006293B (en) Composition and method for seed treatment use
EP2376077A4 (en) COMPOSITION AND METHOD FOR THE TREATMENT OF DIABETES
EP2267217A4 (en) COMPOSITION OF PROCESSING AGENTS FOR TEXTILES
GB0807018D0 (en) Antibodies and treatment
IL207520A0 (en) Carboxamide-heteroaryl derivatives for the treatment of diabetes
EP2480246A4 (en) COMPOSITION AND METHOD FOR THE TREATMENT OF DIABETES
GB2469220B (en) Pharmaceutical composition for treating diabetes and preparation method thereof
HK1168793A1 (en) Glucose metabolism-improving agent and glucose metabolism-improving composition
EP2431041A4 (en) PHARMACEUTICAL COMPOSITION FOR TREATING CARDIOVASCULAR DISORDER AND USE THEREOF
IL202002A0 (en) Method of treating diabetes
EP2512504A4 (en) COMPOSITION AND THERAPEUTIC METHOD
ZA201105441B (en) Ethanamine compounds and their use for treating depression
ZA201006657B (en) Disinfection composition and process
GB0815179D0 (en) Medication and treatment for infection
GB0714500D0 (en) composition and treatment
GB0807102D0 (en) Process and composition
PL384259A1 (pl) Kompozycja farmaceutyczna do leczenia chorób skórnych